Affordable Access

deepdyve-link
Publisher Website

Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.

Authors
  • Holguin, Francia1
  • Rubió-Casadevall, Jordi1, 2
  • Saigi, Maria3
  • Marruecos, Jordi4
  • Taberna, Miren3
  • Tobed, Marc5
  • Maños, Manuel6, 7
  • Mesía, Ricard3, 7
  • 1 a Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital JosepTrueta , Girona , Spain. , (Spain)
  • 2 b Descriptive Epidemiology, Genetics and Cancer Prevention Group , Biomedical Research Institute (IDIBGI) , Girona , Spain. , (Spain)
  • 3 c Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital Duran I Reynalds , L'Hospitalet de LLobregat, Barcelona , Spain. , (Spain)
  • 4 d Deparment of Radiotherapy, Catalan Institute of Oncology , Hospital JosepTrueta , Girona , Spain. , (Spain)
  • 5 e Deparment of Otorhinolaringology , Hospital Universitari JosepTrueta , Servei Català de la Salut, Girona , Spain. , (Spain)
  • 6 f Deparment of Otorhinolaringology , Hospital Universitari de Bellvitge, University of Barcelona , Servei Català de la Salut, Barcelona , Spain. , (Spain)
  • 7 g Medical Oncology Department , Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) , Hospitalet de LLobregat, Barcelona , Spain. , (Spain)
Type
Published Article
Journal
Journal of chemotherapy (Florence, Italy)
Publication Date
Oct 01, 2017
Volume
29
Issue
5
Pages
310–313
Identifiers
DOI: 10.1080/1120009X.2016.1187360
PMID: 27380218
Source
Medline
Keywords
License
Unknown

Abstract

Cetuximab is a monoclonal antibody against epidermal growth factor receptor useful in the treatment of patients with Head and Neck Squamous Cell Carcinoma combined with radiotherapy or chemotherapy. Its pharmacokinetics are not influenced by hepatic status and there are no specific warnings concerning its indication in patients with impaired hepatic function. Patients with a previous liver transplant are at risk for hepatic toxicity and use immunosupressants to avoid rejection that can interact with other drugs. We present two cases of patients with a previous liver transplant in which cetuximab was administered to treat head and neck cancer.

Report this publication

Statistics

Seen <100 times